AIM ImmunoTech completes last dosing in Phase 2 DURIPANC trial of Ampligen plus AstraZeneca Imfinzi in metastatic pancreatic cancer
I'm LongbridgeAI, I can summarize articles.AIM ImmunoTech has completed the last dosing in its Phase 2 DURIPANC trial, evaluating Ampligen combined with AstraZeneca’s Imfinzi for metastatic pancreatic cancer. Primary endpoint analysis is scheduled to begin in December 2026, with topline data expected in Q1 2027. Overall survival analysis will start in June 2027, serving as a key milestone for potential Phase 3 development.
- AIM ImmunoTech completed last dosing in its Phase 2 DURIPANC trial of Ampligen with AstraZeneca’s Imfinzi in metastatic pancreatic cancer. * Results have not been presented; primary endpoint analysis is set to start in December 2026, with topline data expected in Q1 2027. * The readout will indicate whether the combination can deliver meaningful disease control in this hard-to-treat setting. * Overall survival analysis is expected to begin in June 2027, a key inflection point for a potential Phase 3 program. * Earlier exploratory use in a Dutch named-patient program signaled a possible survival benefit in a biomarker-defined subgroup, pending confirmation in trials. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608030833PRIMZONEFULLFEED9801840) on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)